Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2010

01-05-2010 | Original Article

Expression of Urotensin II and Its Receptor in Human Liver Cirrhosis and Fulminant Hepatic Failure

Authors: Ludger Leifeld, Christoph Clemens, Jörg Heller, Jonel Trebicka, Tilman Sauerbruch, Ulrich Spengler

Published in: Digestive Diseases and Sciences | Issue 5/2010

Login to get access

Abstract

Objectives

Urotensin II [U-II] plasma levels are increased in liver cirrhosis [LC] and are discussed as an important mediator of portal hypertension since the U-II antagonist palosuran has beneficial effects on portal hypertension by increasing splanchnic resistance. Nevertheless, no data are available on the intrahepatic expression of U-II and its receptor [UT] in humans.

Methods

U-II and UT expression were analyzed in the livers of patients with LC, fulminant hepatic failure [FHF], and normal controls [NC] using immunohistochemistry.

Results

Both U-II and UT were expressed in the liver on endothelial cells from arteries, veins, and bile ducts as well as on Kupffer cells. In LC, the total number of U-II-expressing cells was 20% lower compared to NC (P < 0.001), while expression of UT did not differ between LC and NC. In contrast, significant enhanced number of U-II and UT positive cells were found in FHF compared to LC and NC (P < 0.001). U-II and UT expression was also found in portal veins, without differences between LC and NC.

Conclusions

Our data demonstrate that U-II and UT are not elevated in human cirrhotic livers but are in livers of patients with FHF.
Literature
1.
3.
4.
go back to reference Song W, Abdel-Razik AE, Lu W, et al. Urotensin II and renal function in the rat. Kidney Int. 2006;69:1360–1368.PubMed Song W, Abdel-Razik AE, Lu W, et al. Urotensin II and renal function in the rat. Kidney Int. 2006;69:1360–1368.PubMed
6.
go back to reference Douglas SA, Ashton DJ, Sauermelch CF, et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol. 2000;36:S163–S166.PubMed Douglas SA, Ashton DJ, Sauermelch CF, et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol. 2000;36:S163–S166.PubMed
7.
go back to reference Douglas SA, Sulpizio AC, Piercy V, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131:1262–1274. doi:10.1038/sj.bjp.0703690.CrossRefPubMed Douglas SA, Sulpizio AC, Piercy V, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131:1262–1274. doi:10.​1038/​sj.​bjp.​0703690.CrossRefPubMed
8.
10.
go back to reference Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol. 2001;280:H925–H928.PubMed Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol. 2001;280:H925–H928.PubMed
12.
go back to reference Kemp W, Krum H, Colman J, et al. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int. 2007;27:1232–1239.PubMed Kemp W, Krum H, Colman J, et al. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int. 2007;27:1232–1239.PubMed
13.
15.
go back to reference O’Grady JG, Schalm S, Williams R. Acute liver failure: redefining the syndroms. Lancet. 1993;342:373–375. O’Grady JG, Schalm S, Williams R. Acute liver failure: redefining the syndroms. Lancet. 1993;342:373–375.
16.
go back to reference Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U. Enhanced expression of CD80 (B7–1), CD86 (B7–2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol. 1999;154:1711–1720.PubMed Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U. Enhanced expression of CD80 (B7–1), CD86 (B7–2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol. 1999;154:1711–1720.PubMed
17.
go back to reference Leifeld L, Cheng S, Ramakers J, et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology. 2002;36:1001–1008.PubMed Leifeld L, Cheng S, Ramakers J, et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology. 2002;36:1001–1008.PubMed
20.
go back to reference Kemp W, Roberts S, Komesaroff PA, Zomer E, Krum H. Urotensin II in chronic liver disease: in vivo effect on vascular tone. Scand J Gastroenterol. 2007;1–7. Kemp W, Roberts S, Komesaroff PA, Zomer E, Krum H. Urotensin II in chronic liver disease: in vivo effect on vascular tone. Scand J Gastroenterol. 2007;1–7.
21.
go back to reference Birker-Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C, Nayler O. The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res. 2003;23:289–305. doi:10.1081/RRS-120026972.CrossRefPubMed Birker-Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C, Nayler O. The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res. 2003;23:289–305. doi:10.​1081/​RRS-120026972.CrossRefPubMed
22.
go back to reference Johns DG, Ao Z, Naselsky D, et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:238–250. doi:10.1007/s00210-004-0980-z.CrossRefPubMed Johns DG, Ao Z, Naselsky D, et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:238–250. doi:10.​1007/​s00210-004-0980-z.CrossRefPubMed
23.
go back to reference Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Bletiere D, Loirand G, Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol. 2007;179:901–909.PubMed Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Bletiere D, Loirand G, Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol. 2007;179:901–909.PubMed
Metadata
Title
Expression of Urotensin II and Its Receptor in Human Liver Cirrhosis and Fulminant Hepatic Failure
Authors
Ludger Leifeld
Christoph Clemens
Jörg Heller
Jonel Trebicka
Tilman Sauerbruch
Ulrich Spengler
Publication date
01-05-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0875-4

Other articles of this Issue 5/2010

Digestive Diseases and Sciences 5/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.